Reports Q4 revenue $25.064M, consensus $29.68M. "In 2022, we focused on executing our strategic vision to advance our differentiated NKT cell therapy platform and reported positive clinical data for our
Reports Q4 revenue $25.064M, consensus $29.68M. "In 2022, we focused on executing our strategic vision to advance our differentiated NKT cell therapy platform and reported positive clinical data for our
Athenex announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15,
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued
Athenex announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom’s, U.K., Medicines and Healthcare Products Regulatory Agency, MHRA, for metastatic breast cancer based
Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly These names in the biotech sector are